Mountain Climber Jeffrey Gottfurcht, founder of the Jeffrey Gottfurcht Children’s Arthritis Foundation, used Nyloxin™ Gel to manage his Rheumatoid Arthritis while climbing the World’s Tallest Mountain.
June 1, 2011 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, is pleased to announce that Jeffrey Gottfurcht’s use of the Nutra Pharma drug, Nyloxin™, helped to successfully manage his Rheumatoid Arthritis pain during his recent Mount Everest climb.
Back in January, Nutra Pharma announced its sponsorship of Gottfurcht’s attempt to be the first person in the world with Rheumatoid Arthritis to climb Mount Everest. Before his journey, he was provided with a supply of Extra Strength Nyloxin™ Gel, an over-the-counter, non-addictive topical gel used for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. The product also comes in an oral spray to treat back pain, neck aches, headaches, joint pain, migraines, and neuralgia. It is available in every-day strength as well as in an extra strength formula for more advanced chronic pain.
Gottfurcht, who lives in the San Francisco area, was diagnosed with Rheumatoid Arthritis (RA) about ten years ago at the age of 28. RA is an autoimmune disease that attacks the joints and causes inflammation, joint pain and stiffness. Patients with severe cases may have deformed hands, wrists or feet and can be bound to a wheel chair. Jeff’s disease inspired him to found the Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF), an organization that grants dreams for juvenile arthritis patients. The Mount Everest climb served to not only meet a personal goal of his, but also to raise the awareness of Rheumatoid Arthritis.
Mr Gottfurcht began using Nyloxin™ while training for his Everest expedition. It was so effective in relieving the pain from his Rheumatoid Arthritis that he was able to stop using other medications with potentially serious side effects. He began his Everest climb in late March, 2011 and despite adverse weather conditions, reached the summit on May 14, using Nyloxin™ every day to manage his RA symptoms. He recently returned home safely from his expedition.
Jeff prefers using Nyloxin™ to other pain medications because it is both safe and effective. “You cannot climb mountains if the medicines you are taking cause prohibitive side effects. Nyloxin™ is ideal for reducing inflammation and controlling my pain, because it works without the limitations of other drugs I was taking for RA. I had one major flare-up early during the Everest trip, but I increased my use of Nyloxin™, and the pain was well under control for the remainder of the climb. I’m grateful to Nutra Pharma for this amazing product and continue to use it daily!”
Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation, commented, “Jeff Gottfurcht is an inspiration to so many others who may be experiencing physical challenges when it comes to reaching their goals. Nutra Pharma is so proud to be a part of Jeff’s success. Our hope is that Jeff’s monumental accomplishment encourages others who are suffering from chronic pain to turn to Nyloxin™ to get relief. Obviously you don’t have to go to the extreme and climb Mt. Everest to have an active lifestyle. There are those of us who simply want to accomplish every day activities without chronic pain getting in the way.”
Jeff Gotturcht added, “If Nyloxin™ can help a man with painful Rheumatoid Arthritis climb 29,035 feet to the top of Mount Everest, it can certainly help others out there who are dealing with chronic pain. I can’t imagine living without it.”
Read Nutra Pharma’s in-depth interview with Jeffrey Gottfurcht about his Everest climb by Clicking Here.
The Jeffrey Gottfurcht Children’s Arthritis Foundation was founded by Jeffrey Gottfurcht as a way to inspire, educate and generate awareness of both rheumatoid and juvenile idiopathic arthritis, as those suffering optimistically await a cure. In 2002, at the age of 28, Gottfurcht was diagnosed with RA and after undergoing years of treatment, he wanted to share his determination to fight the disease while bringing joy, strength and support to children and young adults similarly afflicted. A wish-granting Foundation, JGCAF accepts referrals for dreams from parents, guardians, siblings, members of the medical community, and directly from children suffering from juvenile rheumatoid arthritis. The Foundation’s Dream Team helps select dreams that are prudent and possible and assists in making them come true. Help us fulfill a dream of a child living with Juvenile Arthritis today. For more information please call 310.855.3745 or visit www.JGCAF.org.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit:
Nutra Pharma Corp.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Company's sponsorship of Jeffrey Gottfurcht should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.